Newsroom

Seoul, South Korea, April 1, 2026 - LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announced that it has entered into a contract development and manufacturing agreement with a U.S.-based biotech company specializing in oncology, covering the production of antibody drug substance and process development.

Under this agreement, LOTTE Biologics will support the manufacturing of antibody drug substance required for late-stage clinical trials, as well as process optimization at commercial-ready scale. These activities will be carried out at the company’s Syracuse Bio Campus in New York.

This collaboration represents a strategic project that goes beyond the production of clinical trial materials, encompassing both late-stage clinical development and future potential of commercialization. For antibody therapeutics, establishing a robust process early is widely recognized as a critical determinant of commercial success. Leveraging its proven manufacturing capabilities and large-scale production infrastructure, LOTTE Biologics is well positioned to support the program through clinical development and readiness for commercialization in a stable and reliable manner.

Building on its growing track record of global partnerships, LOTTE Biologics continues to position the Syracuse Bio Campus as a key hub for expanding collaboration with late-stage clients. In parallel, through integration with the Songdo Bio Campus - scheduled for mechanical completion this year - the company plans to further strengthen its client-centric, end-to-end CDMO services and supply chain management capabilities, supported by a unified quality system across dual sites.

A LOTTE Biologics representative stated, “This contract represents an important step in building a foundation for large-scale global projects. We will continue to actively pursue additional opportunities to support clients through commercialization and beyond.”